Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: A randomized, controlled trial

Annals of Internal Medicine

Volumn 143, Issue 8, 2005, Pages

  Rosenstock, Julio ^a   Zinman, Bernard ^b   Murphy, Liam J ^b   Clement, Stephen C ^b   Moore, Paul ^b   Bowering, C Keith ^b   Hendler, Rosa ^b   Lan, Shu Ping ^b   Cefalu, William T ^b  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLIBENCLAMIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ANTIBODY; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; ASTHENIA; BODY WEIGHT; CANADA; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; EVALUATION; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPESTHESIA; HYPOGLYCEMIA; LIPID BLOOD LEVEL; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOMES RESEARCH; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SWEATING; TITRIMETRY; TREATMENT FAILURE; TREMOR; UNITED STATES; WEIGHT GAIN; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN ANTIBODIES; MALE; MIDDLE AGED; WEIGHT GAIN;

EID: 26944435504     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-143-8-200510180-00005     Document Type: Article

References (42)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977-86. [PMID: 8366922]
2. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329:304-9. [PMID: 8147960]
3. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563-9. [PMID: 12020338]
4. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-17. [PMID: 7587918]
5. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia. 1996;39:1577-83. PMID: [8960845]
6. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-53. [PMID: 9742976]
7. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854-65. [PMID: 9742977]
8. Stratum IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-12. [PMID: 10938048]
9. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23 Suppl 2:B21-9. [PMID: 10860187]
10. Chehade JM, Mooradian AD. A rational approach to drug therapy of type 2 diabetes mellitus. Drugs. 2000;60:95-113. [PMID: 10929931]
11. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287:360-72. [PMID: 11790216]
12. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care. 2001;24:758-67. [PMID: 11315844]
13. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-6. [PMID: 14578243]
14. Rosenstock J. Basal insulin supplementation in type 2 diabetes; refining the tactics. Am J Med. 2004;116 Suppl 3A:10S-16S. [PMID: 15013455]
15. Riddle MC. The underuse of insulin therapy in North America. Diabetes Metab Res Rev. 2002;18 Suppl 3:S42-9. [PMID: 12324985]
16. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002;26 Suppl 3:S18-24. [PMID: 12174319]
17. Zambanini A, Newson RB, Maisey M, Feher MD. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract. 1999;46:239-46. [PMID: 10624790]
18. Mollema ED, Snoek FJ, Heine RJ, van der Ploeg HM. Phobia of self-injecting and self-testing in insulin-treated diabetes patients: opportunities for screening. Diabet Med. 2001;18:671-4. [PMID: 11553207]
19. Rosenstock J, Wyne K. Insulin treatment in type 2 diabetes. In: Goldstein BJ, Müller-Wieland D, eds. Textbook of Type 2 Diabetes. London: Martin Dunitz; 2003:131-54.
20. Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet. 2004;43:781-801. [PMID: 15355125]
21. Rave K, Bott S, Heinemann L, Sha S, Becker RH, Willavize SA, et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care. 2005;28:1077-82. [PMID: 15855570]
22. Quattrin T, Bélanger A, Bohannon NJ, Schwartz SL. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care. 2004;27:2622-7. [PMID: 15504996]
23. Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS, et al. Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care. 2004;27:2356-62. [PMID: 15451900]
24. Weiss SR, Cheng SL, Kourides IA, Gelfand RA, Landschulz WH. Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial. Arch Intern Med. 2003;163:2277-82. [PMID: 14581245]
25. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1998;21(Suppl 1):S5-19.
26. Franz MJ, Horton ES Sr, Bantle JP, Beebe CA, Brunzell JD, Coulston AM, et al. Nutrition principles for the management of diabetes and related complications. Diabetes Care. 1994;17:490-518. [PMID: 8062628]
27. American Diabetes Association. Diabetes mellitus and exercise. Diabetes Care. 1998;21(Suppl 1):S40-4.
28. Hsu JC. Multiple Comparisons: Theory and Methods. New York: Chapman & Hall; 1996.
29. Marcus R, Peritz E, Garbriel KR. On closed testing procedures with special reference to ordered analysis of variance. Biometrika. 1976;63:655-60.
30. Testa MA, Turner RR, Hayes JF, Simonson DC. Intensive therapy and patient satisfaction in type 1 diabetes: a randomized trial of injected vs. inhaled insulin [Abstract]. Diabetologia. 2001;44:A4.
31. Dreyer M. Efficacy and 2-year pulmonary safety data of inhaled insulin as adjunctive therapy with metformin or glibenclamide in type 2 diabetes patients poorly controlled with oral monotherapy [Abstract]. Diabetologia. 2004;47:A44.
32. Skyler J. Sustained long-term efficacy and safety of inhaled insulin (Exubera) during 4 years of continuous therapy [Abstract]. Diabetes. 2004;53:A115.
33. Van Haeften TW, Krom BA, Gerich JE. Prolonged fasting hypoglycemia due to insulin antibodies in patient with non-insulin-dependent diabetes mellitus: effect of insulin withdrawal on insulin-antibody-binding kinetics. Diabetes Care. 1987;10:160-3. [PMID: 3582076]
34. Stoever JA, Palmer JP. Inhaled insulin and insulin antibodies: a new twist to an old debate. Diabetes Technol Ther. 2002;4:157-61. [PMID: 12079619]
35. Fineberg SE, Kawabata T, Finco-Kent D, Liu C, Krasner A. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J Clin Endocrinol Metab. 2005;90:3287-94. [PMID: 15741258]
36. A desktop guide to type 2 diabetes mellitus. European Diabetes Policy Group 1999. Diabet Med. 1999;16:716-30. [PMID: 10510947]
37. Standards of medical care in diabetes. Diabetes Care. 2004;27 Suppl 1:S15-35. [PMID: 14693923]
38. Rosenstock J, Riddle M. Insulin therapy in type 2 diabetes. In: Cefalu WT, Gerich JE, LeRoith D, eds. The CADRE Handbook of Diabetes Management. New York: Medical Information Pr; 2004:145-68.
39. Gerber RA, Cappelleri JC, Kourides IA, Gelfand RA. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: a randomized controlled trial. Diabetes Care. 2001;24:1556-9. [PMID: 11522698]
40. Cappelleri JC, Cefalu WT, Rosenstock J, Kourides IA, Gerber RA. Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clin Ther. 2002;24:552-64. [PMID: 12017400]
41. Rosenstock J, Cappelleri JC, Bolinder B, Gerber RA. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care. 2004;27:1318-23. [PMID: 15161782]
42. Freemantle N, Blonde L, Duhot D, Hompesch M, Eggertsen R, Hobbs FD, et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care. 2005;28:427-8. [PMID: 15677807]